[{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio Announces Design for Second Pivotal Clinical Trial of Zimura\u00ae in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio Provides Update on the Initiation of the Second Pivotal Clinical Trial Enrollment for Zimura","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable "},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio Announces Fast Track Designation from FDA for Zimura\u00ae for the Treatment of Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio to Announce Zimura\u00ae 18 Month Data from the OPH2003 Phase 3 Clinical Trial in Geographic Atrophy Secondary to Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio Announces First Patient Dosed in Second Zimura\u00ae Phase 3 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC Bio Publishes GATHER1 Phase 3 Clinical Trial Results for Zimura\u00ae in Geographic Atrophy Secondary to Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio to Present Zimura GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyses","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura\u00ae Ahead of Schedule","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Gets FDA Agreement Under SPA for GATHER2 Phase 3 Zimura\u00ae Trial in Geographic Atrophy Secondary to AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial of Zimura\u00ae in Patients with Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"DelSiTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$1.2 million","newsHeadline":"Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Sustained-Release","sponsorNew":"IVERIC bio \/ DelSiTech","highestDevelopmentStatusID":"10","companyTruncated":"IVERIC bio \/ DelSiTech"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura\u00ae at American Society of Retina Specialists Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iveric Bio Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silicon Valley Bank","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Financing","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Hercules Capital"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces Positive Topline Data from Zimura\u00ae GATHER2 Phase 3 Clinical Trial in Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces Vision Loss Reduction Data in Geographic Atrophy from Avacincaptad Pegol GATHER Trials","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Not Applicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$5,900.0 million","upfrontCash":"$5,900.0 million","newsHeadline":"Astellas Enters Into Definitive Agreement to Acquire Iveric Bio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":5.9000000000000004,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":5.9000000000000004,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Astellas Pharma"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$5,900.0 million","upfrontCash":"$5,900.0 million","newsHeadline":"Astellas Completes Acquisition of Iveric Bio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":5.9000000000000004,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":5.9000000000000004,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Receives U.S. FDA Approval for IZERVAY\u2122 (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"IVERIC bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Iveric Bio\u2019s Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Astellas Pharma \/ Iveric Bio","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Iveric Bio"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY\u2122 (avacincaptad pegol intravitreal solution) for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio \/ Astellas Pharma"}]
Find Clinical Drug Pipeline Developments & Deals for Avacincaptad Pegol
Details :
IZERVAY™ (avacincaptad pegol intravitreal solution), a complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Details :
Izervay (avacincaptad pegol intravitreal solution) act as completent C5 inhibitor that is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Details :
IZERVAY (avacincaptad pegol intravitreal solution) act as completent C5 inhibitor that is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Details :
Through the acquisition, Astellas expands its ophthalmology pipeline through Iveric Bio's promising programs, including Zimura (avacincaptad pegol), an important program for Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).
Details :
Through the acquisition, Astellas will expand its ophthalmology pipeline through Iveric Bio's promising programs, including Zimura (avacincaptad pegol), an important program for Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).
Details :
Zimura (avacincaptad pegol) is a novel complement C5 protein inhibitor having the potential to decrease activity of the complement system that causes the degeneration of retinal cells and potentially slow the progression of geographic atrophy.
Details :
Zimura (avacincaptad pegol) is a novel complement C5 protein inhibitor by targeting C5, ACP has the potential to decrease activity of the complement system that causes the degeneration of retinal cells and potentially slow the progression of GA.
Details :
Zimura (avacincaptad pegol), is an investigational drug that has not yet been evaluated by any regulatory body for safety and efficacy. ACP is not authorized for any indication in any country.
Details :
Zimura (ACP) is novel complement C5 protein inhibitor. Overactivity of the complement system and the C5 protein are suspected to play a critical role in development and growth of scarring and vision loss associated with GA secondary to AMD.
Details :
Zimura (avacincaptad pegol) showed Primary Endpoint Met with 14.3% Reduction (p-value = 0.0064) in Mean Rate of Growth (Slope) in GA Area Over 12 Months Using Square Root Transformation; 17.7% Reduction (p-value = 0.0039) Using Observed GA Area
Market Place
Reset All
